Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
source: pixabay.com

Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval

According to a story from BioSpace, the biopharmaceutical company Kite announced recently that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has released…

Continue Reading Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
source: pixabay.com

This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions

  A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…

Continue Reading This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
source: pixabay.com

This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions

  A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…

Continue Reading This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research

According to a story from curetoday.com, a recent Phase 2 trial has demonstrated that bortezomib (marketed as Velcade) has the potential to be an effective therapy for patients with mantle…

Continue Reading Clinical Trial Results With Velcade in Mantle Cell Lymphoma Inspire Continued Research
A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Source: Pixabay.com

A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients

Mantle cell lymphoma is caused by a genetic mutation which  produces cancerous white blood cells. Of course, these are the cells which fight infection in a normal body. Therefore in…

Continue Reading A New Combination of Therapies has Potential to Treat all Mantle Cell Lymphoma Patients
Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment
PixelAnarchy / Pixabay

Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment

According to a story from news.com.au, patients in Western Australia will start getting much cheaper access to a highly valuable treatment next month for a rare form of cancer called…

Continue Reading Mantle Cell Lymphoma Patients in Western Australia Will Get Much Cheaper Access to Essential Treatment
Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
source: pixabay.com

Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients

According to a story from adc.net.au, an innovative new cancer treatment regimen is responsible for doubling survival rates for patients with certain types of rare, difficult-to-treat blood cancers. This combination…

Continue Reading Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients